Potential Use of Bispecific Antibodies (BSABS) for Targeting Gliomas and Melanomas

  • Liang Liu
  • Rolf F. Barth
  • Dianne M. Adams
  • Albert H. Soloway
  • Ralph A. Reisfeld


A major requirement for the success of BNCT is the selective delivery of boron to individual tumor cells 1,2. Monoclonal antibodies (MoAbs) have been used as selective delivery agents for drugs, toxins and radionuclides to tumor cells for cancer therapy3. However, one major limitation of boron containing immunoconjugates is that their tumor localizing properties may be significantly reduced when compared to native, unmodified antibodies4,5. Primarily for this reason we have been interested in the possibility of using bispecific antibodies (BsAbs) for tumor targeting. BsAbs have two distinct antigen combining sites, one of which can bind to a tumor associated antigen on the cell surface, and the other to a tumoricidal agent6. Since BsAbs have not been chemically modified, they presumably have both immunoreactivity and distribution profiles that are similar to native MoAbs. BsAbs can be produced by fusing two different hybridoma cell lines to produce a hybrid-hybridoma (quadroma). In the present report, we describe the production of quadro-mas secreting BsAbs reactive with polyhedral borane anions and a tumor associated cell surface proteoglycan expressed on glioblastomas and melanomas7.


Boron Neutron Capture Therapy Boron Compound Bispecific Antibody Sodium Borocaptate Tumoricidal Agent6 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    R.F.Barth, A.H.Soloway, and R.G.Fairchild, Boron neutron capture therapy of cancer. Cancer:Res. 50: 1061–1070, 1990.PubMedGoogle Scholar
  2. 2.
    M.F.Hawthorne, The role of chemistry in the development of boron neutron capture therapy of cancer. Angew.Chem.Int.Ed.Engl, 32: 950–984, 1993.CrossRefGoogle Scholar
  3. 3.
    T.A.Waldmann, Monoclonal antibodies in diagnosis and therapy. Science., 252: 1657–1662, 1991.PubMedCrossRefGoogle Scholar
  4. 4.
    R.F.Barth, N.Mafune, F.Alam, D.M.Adams, A.H.Soloway, G.E.Makroglou, et al, Conjugation, purification and characterization of boronated monoclonal antibodies for use in neutron capture therapy. Strahlenther und Onkol., 165: 142–145, 1989.Google Scholar
  5. 5.
    R.F.Barth, D.M.Adams, A.H.Soloway, F.Alam, and M.V.Darby, Boronated starburst dendrimer-monoclonal antibody immunoconjugates: evaluation as a potential delivery system for neutron capture therapy. Bioconjugate Chem., 5: 58–66, 1994.CrossRefGoogle Scholar
  6. 6.
    O.Nolan and R.O’Kennedy, Bifunctional antibodies: concept, production and applications. Biochemica et Biophysica Acta, 1040: 1–11, 1990.CrossRefGoogle Scholar
  7. 7.
    A.C.Morgan, D.R.Galloway, and R.A.Reisfeld, Production and characterization of monoclonal antibody to a melanoma specific glycoprotein. Hybridoma, 1:27–36, 1981.PubMedCrossRefGoogle Scholar
  8. 8.
    R.F.Barth, D.M.Adams, A.H.Soloway, E.B.Mechetner, F.Alam, and A.K.M.Anisuzzaman, Determination of boron in tissues and cells using direct current plasma atomic emisson spectroscopy. Anal.Chem., 63: 890–892, 1991.PubMedCrossRefGoogle Scholar
  9. 9.
    O.A.Oredipe, R.F.Barth, J.H.Rotaru, and Z.Steplewski, Modulation of monoclonal antibody affinity and antigenic receptor site expression on human colorectal cancer cells. Antibody, lmmunoconiugates, and Radiopharmaceuticals, 5: 295–306, 1992.Google Scholar
  10. 10.
    M.Schrappe, G.F.Klier, R.C.Spiro, T.A.Waltz, R.A.Reisfeld, and C.L.Gladson, Correlation ofchondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial cells with the malignant phentype of astroglical cells. Cancer Res. 51: 4986–93, 1991.PubMedGoogle Scholar
  11. 11.
    L. Liu, R.F. Barth, D.M. Adams, A.H. Soloway, and R. Reisfeld. Bispecific antibodies as targetins agents for boron neutron capture therapy of brain tumors. J. Hematother. 4: 447–483, 1995.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Liang Liu
    • 1
  • Rolf F. Barth
    • 1
  • Dianne M. Adams
    • 1
  • Albert H. Soloway
    • 2
  • Ralph A. Reisfeld
    • 3
  1. 1.Department of PathologyThe Ohio State UniversityColumbusUSA
  2. 2.College of PharmacyThe Ohio State UniversityColumbusUSA
  3. 3.Scripps Research InstituteLa JollaUSA

Personalised recommendations